MOH Research Note — The Cost Ratio Test
Molina’s cash flow supports the recovery case, while Marketplace losses and the October medical-cost test keep conviction limited.
Research Notes
HBAN Research Note — The Reserve Test
HBAN remains profitable, but falling CRE reserve coverage and faster nonaccrual growth make the October credit disclosure the central evidence test.
FITBPA Research Note — Credit Holds, Rates Decide
Fifth Third credit remains sound, but FITBPA closed near a fresh one-year low as long Treasury yields kept pressure on perpetual preferreds.
MS Research Note — Strong Quarter, Full Price
Record wealth flows and a 26.6% return support the franchise case, but the valuation already assumes durable execution.
UNH Research Note — Recovery Still Has Conditions
UnitedHealth has two quarters of medical-cost improvement, but the recovery remains narrow and legal risk is unresolved.
NVDA Research Note — The Proof Is August 26
NVIDIA retains exceptional growth and margins, while a fuller valuation makes the August 26 report the next decisive evidence point.
VRT Research Note — Backlog Meets the Conversion Test
Orders and backlog surged, but the July revenue shortfall leaves conversion as the central evidence test.
BIVI Research Note — Evidence Before Optimism
BioVie’s subgroup signal does not resolve the missing registered endpoint or the scale of pending dilution.
VICI Research Note — The Tenant Concentration Test
VICI looks inexpensive on AFFO and yield, but Caesars lease talks and two-tenant concentration explain why the discount persists.
WULF Research Note — Backlog Meets Dilution
WULF’s HPC mix shifted sharply, but declining revenue, negative adjusted EBITDA and a rising share count keep financing quality central.